Top 5 Global Pharma Companies
Brochure
More information from http://www.researchandmarkets.com/reports/680564/
The Top Five Global Pharma Companies; Where they are Now and
Where they heading?
Description:
A mini report identifying drivers and barriers to sustaining financial performance over the next 5 years for the top five global pharmaceutical companies -Johnson & Johnson, Pfizer, GSK, Novartis and Sanofi-Aventis
This report presents the cases of the top five global pharma companies: J&J, Pfizer, GSK, Novartis and Sanofi-Aventis and identifies their key growth areas. Pooling data from 6 major investment institutions, it delivers a 360o analysis on these big five global pharma with further value add and refinement coming from 8 leading key opinion leaders, to produce an easy to read 25 page
PowerPoint deck.
Johnson & Johnson has reached a critical point in its product portfolio which should see the company convert from “cash cow” (high market share; low market growth) to “star” (high market share; high market growth) status by 2010. This is reflected in J&J having not less than 6 late stage drugs that will either unveil phase III data or be filed with the FDA within 2008 culminating in strong impact on its P&L account by 2010.
Likewise the other cash cow Pfizer, boasts of at least 17 disclosed products under late phase development, with launches in the post-2010 period, thus are likely to buoy double digit sales growth beyond Lipitor patent expiry.
GlaxoSmithKline on the other hand, has a product portfolio with a significant cash flow position this in turn has spurred on a meaningful gearing by GSK management. This puts the company firmly in a star performing position for 2008-2011. With asset consolidation of $23.5bn USD over three years post-2009, the company is likely to attain double-digit earnings growth out to 2011 with middigit growth in 2012 impacted by generic competition.
In the same star category is Novartis with top-line growth driven by a combination
More information from http://www.researchandmarkets.com/reports/680564/
The Top Five Global Pharma Companies; Where they are Now and
Where they heading?
Description:
A mini report identifying drivers and barriers to sustaining financial performance over the next 5 years for the top five global pharmaceutical companies -Johnson & Johnson, Pfizer, GSK, Novartis and Sanofi-Aventis
This report presents the cases of the top five global pharma companies: J&J, Pfizer, GSK, Novartis and Sanofi-Aventis and identifies their key growth areas. Pooling data from 6 major investment institutions, it delivers a 360o analysis on these big five global pharma with further value add and refinement coming from 8 leading key opinion leaders, to produce an easy to read 25 page
PowerPoint deck.
Johnson & Johnson has reached a critical point in its product portfolio which should see the company convert from “cash cow” (high market share; low market growth) to “star” (high market share; high market growth) status by 2010. This is reflected in J&J having not less than 6 late stage drugs that will either unveil phase III data or be filed with the FDA within 2008 culminating in strong impact on its P&L account by 2010.
Likewise the other cash cow Pfizer, boasts of at least 17 disclosed products under late phase development, with launches in the post-2010 period, thus are likely to buoy double digit sales growth beyond Lipitor patent expiry.
GlaxoSmithKline on the other hand, has a product portfolio with a significant cash flow position this in turn has spurred on a meaningful gearing by GSK management. This puts the company firmly in a star performing position for 2008-2011. With asset consolidation of $23.5bn USD over three years post-2009, the company is likely to attain double-digit earnings growth out to 2011 with middigit growth in 2012 impacted by generic competition.
In the same star category is Novartis with top-line growth driven by a combination